WO2011098578A3 - Liposome system for ocular administration - Google Patents
Liposome system for ocular administration Download PDFInfo
- Publication number
- WO2011098578A3 WO2011098578A3 PCT/EP2011/052061 EP2011052061W WO2011098578A3 WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3 EP 2011052061 W EP2011052061 W EP 2011052061W WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposomes
- pharmaceutical formulation
- eye
- active ingredient
- ocular administration
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 230000003111 delayed effect Effects 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention concerns a pharmaceutical formulation for ocular or intra-ocular administration providing sustained or delayed release of at least one active ingredient, said pharmaceutical formulation comprising liposomes, said liposomes comprising at least part of said at least one active ingredient, at least part of said liposomes exhibiting a charge increasing the adherence of the charged liposomes to the eye after administration, in particular when said pharmaceutical formulation is for ocular administration, and wherein at least one of the lipids in the liposomes is degradable by sPLA2 activity, allowing sustained or delayed release of said at least one active ingredient from said liposomes upon contact with tear fluid or with sPLA2 in the eye or in the vicinity of the eye. The pharmaceutical formulation is useful for ophthalmic indications.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30375810P | 2010-02-12 | 2010-02-12 | |
| DKPA201070051 | 2010-02-12 | ||
| US61/303,758 | 2010-02-12 | ||
| DKPA201070051 | 2010-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2011098578A2 WO2011098578A2 (en) | 2011-08-18 |
| WO2011098578A3 true WO2011098578A3 (en) | 2011-10-20 |
Family
ID=44280689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2011/052061 WO2011098578A2 (en) | 2010-02-12 | 2011-02-11 | Liposome system for ocular administration |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011098578A2 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| US10272040B2 (en) | 2010-08-12 | 2019-04-30 | Nanyang Technological University | Liposomal formulation for ocular drug delivery |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| US9956195B2 (en) * | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016048242A1 (en) * | 2014-09-24 | 2016-03-31 | Nanyang Technological University | Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension |
| EP3198035B1 (en) | 2014-09-26 | 2022-11-02 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| JP2018521000A (en) | 2015-05-29 | 2018-08-02 | シドネキシス，インク． | Pharmaceutical formulation stabilized with D2O |
| WO2017027017A1 (en) * | 2015-08-11 | 2017-02-16 | Peregrine Ophthalmic PTE LTD. | Stable liposomal formulations of carbonic anhydrase inhibitors for ocular drug delivery |
| US20170119666A1 (en) * | 2015-10-29 | 2017-05-04 | Peregrine Ophthalmic PTE LTD. | Stable liposomal formulations of alpha 2 adrenergic agonists for ocular delivery |
| US20190133931A1 (en) * | 2016-04-19 | 2019-05-09 | Nanyang Technological University | Subconjunctival depot forming formulations for ocular drug delivery |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) * | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2018283250B2 (en) | 2017-06-16 | 2022-09-01 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| JP2020536955A (en) | 2017-10-06 | 2020-12-17 | ファウンドリー セラピューティクス， インコーポレイテッド | Implantable depot for controlled release of therapeutic agent |
| CN107982219B (en) * | 2017-11-30 | 2020-09-15 | 天津中医药大学 | Cationic modified pilocarpine hydrochloride flexible nanoliposome ophthalmic preparation and preparation method |
| CN113244171A (en) * | 2021-01-28 | 2021-08-13 | 周斌 | Timolol maleate liposome gel and preparation method thereof |
| US12153287B2 (en) | 2022-09-27 | 2024-11-26 | Coopervision International Limited | Sustained fatty acid release from contact lens |
| US20240118559A1 (en) | 2022-09-27 | 2024-04-11 | Coopervision International Limited | Sustained release of oleic acid from contact lenses |
| CN117643573B (en) * | 2024-01-29 | 2024-05-03 | 天津医科大学眼科医院 | Nanometer eye drop capable of delivering medicine to posterior segment of eye, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
| US5665770A (en) * | 1993-11-05 | 1997-09-09 | Gakko Hojin Kinki Daigaku | Method for treatment of cataract with radical scavenger |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0651638B2 (en) | 1989-02-13 | 1994-07-06 | 新技術事業団 | Eye drops for corneal epithelial wound treatment |
| PT1254143E (en) | 2000-02-10 | 2005-02-28 | Liplasome Pharma As | ADMINISTRATION SYSTEMS OF LIPID-BASED DRUGS CONTAINING PHOSPHOLIPASE A2 DEGRADABLE LIPID DERIVATIVES AND THEIR THERAPEUTIC UTILIZATION |
| CA2647779A1 (en) | 2006-03-23 | 2007-09-27 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
-
2011
- 2011-02-11 WO PCT/EP2011/052061 patent/WO2011098578A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
| US5665770A (en) * | 1993-11-05 | 1997-09-09 | Gakko Hojin Kinki Daigaku | Method for treatment of cataract with radical scavenger |
| US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| AL-MUHAMMED J ET AL: "IN-VIVO STUDIES ON DEXAMETHASONE SODIUM PHOSPHATE LIPOSOMES", JOURNAL OF MICROENCAPSULATION, vol. 13, no. 3, 1 January 1996 (1996-01-01), TAYLOR AND FRANCIS, BASINGSTOKE, GB, pages 293 - 305, XP009000577, ISSN: 0265-2048 * |
| LAW S L ET AL: "Acyclovir-containing liposomes for potential ocular delivery - Corneal penetration and absorption", JOURNAL OF CONTROLLED RELEASE, vol. 63, no. 1-2, 1 January 2000 (2000-01-01), ELSEVIER, AMSTERDAM, NL, pages 135 - 140, XP004185078, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(99)00192-3 * |
| SCHAEFFER H E ET AL: "LIPOSOMES IN TOPICAL DRUG DELIVERY", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 22, no. 2, 1982, pages 220 - 227, XP002654442, ISSN: 0146-0404 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011098578A2 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011098578A3 (en) | Liposome system for ocular administration | |
| WO2012071476A3 (en) | Drug eluting ocular implant | |
| WO2010068281A3 (en) | Contact lens drug delivery device | |
| WO2012091523A8 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
| WO2012002640A3 (en) | Transdermal drug delivery system containing donepezil | |
| WO2014165308A3 (en) | Microsphere drug delivery system for sustained intraocular release | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| WO2011091205A3 (en) | Intracameral sustained release therapeutic agent implants | |
| PL2262476T3 (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops. | |
| WO2012021107A8 (en) | A liposomal formulation for ocular drug delivery | |
| WO2011014587A3 (en) | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists | |
| WO2010146591A3 (en) | Methods and devices for delivery of pharmaceutical agents within orifices of the body | |
| WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| JP2012533517A5 (en) | ||
| WO2015023884A3 (en) | Timed release of substances to treat ocular disorders | |
| MX2013000661A (en) | Eye drug delivery system. | |
| WO2012112638A8 (en) | Ocular strips | |
| WO2012092510A3 (en) | Ocular drug delivery system | |
| WO2011159761A3 (en) | Punctal plugs with continuous or pulsatile drug release mechanism | |
| PH12021551412A1 (en) | Ursodeoxycholic acid-containing agent for treating or preventing presbyopia | |
| WO2011076368A3 (en) | Topical ophthalmic peptide formulation | |
| WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
| WO2013032643A3 (en) | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells | |
| WO2008027793A3 (en) | Ophthalmic pharmaceutical compositions and uses thereof | |
| EP3587392A8 (en) | Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11702670 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11702670 Country of ref document: EP Kind code of ref document: A2 |